8-K

                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
                       THE SECURITIES EXCHANGE ACT OF 1934

                                 Date of Report
                (Date of earliest event reported): July 27, 2004

                           ARIAD PHARMACEUTICALS, INC.
             (Exact Name of Registrant as Specified in its Charter)


          Delaware                       0-21696                22-3106987
- ----------------------------      -----------------------  ------------------
(State or Other Jurisdiction     (Commission File Number)    (I.R.S. Employer
    of Incorporation)                                      Identification No.)


                              26 LANDSDOWNE STREET
                         CAMBRIDGE, MASSACHUSETTS 02139
              (Address of principal executive offices and zip code)


               Registrant's telephone number, including area code:
                                 (617) 494-0400








ITEM 5. OTHER EVENTS

On July 27, 2004, the Registrant disseminated a Press Release announcing that it
will provide a live webcast of its corporate  presentation at the Adams Harkness
24th Annual  Summer  Seminar on Tuesday,  August 3, 2004,  at the Marriott  Long
Wharf Hotel in Boston.  The presentation  will be given at 2 p.m. (ET) by Harvey
J. Berger, M.D., chairman and chief executive officer of ARIAD, who will provide
an overview of the Company and its progress in key programs.

The  information  contained  in the  Press  Release  dated  July  27,  2004,  is
incorporated herein by reference and attached as Exhibit 99.1 hereto.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.


           (c)    Exhibits.

                  99.1     The Registrant's Press Release dated July 27, 2004.



                                   SIGNATURES

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
Registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


                                             ARIAD PHARMACEUTICALS, INC.



                                             By:    /s/ Edward M. Fitzgerald
                                             ----------------------------------
                                                    Edward M. Fitzgerald
                                                    Senior Vice President and
                                                      Chief Financial Officer


Date:    July 27, 2004


                                        2


                                 EXHIBIT INDEX

Exhibit                                                            Sequential
Number     Description                                             Page Number
- --------   -----------                                             -----------
99.1       The Registrant's Press Release dated July 27, 2004.         4


                                       3

EX-99.1

                                                                    Exhibit 99.1

       ARIAD Announces Webcast of Its Corporate Presentation at
                       Adams Harkness Conference

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 27, 2004--ARIAD
Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that it will
provide a live webcast of its corporate presentation at the Adams
Harkness 24th Annual Summer Seminar on Tuesday, August 3, 2004, at the
Marriott Long Wharf Hotel in Boston. The presentation will be given at
2 p.m. (ET) by Harvey J. Berger, M.D., chairman and chief executive
officer of ARIAD, who will provide an overview of the Company and its
progress in key programs.
    A direct link to the audio portion of the live presentation can be
accessed at ARIAD's website (http://www.ariad.com/investor) by
clicking on this link. An archived audio webcast also will be
available beginning approximately two hours after completion of the
presentation until 5:00 p.m. (ET) on August 10, 2004. To ensure a
timely connection to the live webcast, it is recommended that
participants register at least fifteen minutes prior to the scheduled
webcast.
    Minimum requirements to listen to the audio webcast are Microsoft
Windows Media Player software (free download at
http://www.microsoft.com/windows/windowsmedia/download/default.asp)
and at least a 28.8 Kbps bandwidth connection to the Internet.
    Further information about the conference can be found on the web
at http://www.ahh.com/about_us/conferences_and_events/index.html
(click on "Upcoming Conferences").

    ARIAD is engaged in the discovery and development of breakthrough
medicines to treat cancer by regulating cell signaling with small
molecules. The Company is developing a comprehensive approach to
patients with cancer that addresses the greatest medical need -
aggressive and advanced-stage cancers for which current treatments are
inadequate. ARIAD also has an exclusive license to pioneering
technology and patents related to certain NF-(kappa)B treatment
methods, and the discovery and development of drugs to regulate
NF-(kappa)B cell-signaling activity.

    Additional information about ARIAD can be found on the web at
http://www.ariad.com.

    Some of the matters discussed herein are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements are identified by the use of words
such as "anticipate," "estimate," "expect," "project," "intend,"
"plan," "believe," and other words and terms of similar meaning in
connection with any discussion of future operating or financial
performance. Such statements are based on management's current
expectations and are subject to certain factors, risks and
uncertainties that may cause actual results, outcome of events, timing
and performance to differ materially from those expressed or implied
by such forward-looking statements. These risks include, but are not
limited to, risks and uncertainties regarding the Company's ability to
accurately estimate the actual research and development expenses and
other costs associated with the preclinical and clinical development
of our product candidates, the adequacy of our capital resources and
the availability of additional funding, risks and uncertainties
regarding the Company's ability to successfully conduct preclinical
and clinical studies of its product candidates, risks and
uncertainties that clinical trial results at any phase of development
may be adverse or may not be predictive of future results or lead to
regulatory approval of any of the Company's product candidates, and
risks and uncertainties relating to regulatory oversight, intellectual
property claims, the timing, scope, cost and outcome of legal
proceedings, future capital needs, key employees, dependence on the
Company's collaborators and manufacturers, markets, economic
conditions, products, services, prices, reimbursement rates,
competition and other risks detailed in the Company's public filings
with the Securities and Exchange Commission, including ARIAD's Annual
Report on Form 10-K for the fiscal year ended December 31, 2003. The
information contained in this document is believed to be current as of
the date of original issue. The Company does not intend to update any
of the forward-looking statements after the date of this document to
conform these statements to actual results or to changes in the
Company's expectations, except as required by law.

    CONTACT: ARIAD Pharmaceuticals, Inc.
             Tom Pearson, 610-407-9260
             or
             Kathy Lawton, 617-621-2345